192 related articles for article (PubMed ID: 35999803)
1. The unexpected benefits of sodium glucose co-transporter 2 (SGLT2) Inhibitors.
Chan CG; Stewart R
N Z Med J; 2022 Aug; 135(1560):99-104. PubMed ID: 35999803
[TBL] [Abstract][Full Text] [Related]
2. SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction.
Jhund PS
Heart Fail Clin; 2022 Oct; 18(4):579-586. PubMed ID: 36216487
[TBL] [Abstract][Full Text] [Related]
3. Chapter 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure.
Greene SJ; Butler J; Kosiborod MN
Am J Med; 2024 Feb; 137(2S):S25-S34. PubMed ID: 38184323
[TBL] [Abstract][Full Text] [Related]
4. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions.
Lan NSR; Fegan PG; Yeap BB; Dwivedi G
ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090
[TBL] [Abstract][Full Text] [Related]
5. The Impact of SGLT2 Inhibitors on Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction.
Starr JA; Pinner NA
Ann Pharmacother; 2024 May; 58(5):506-513. PubMed ID: 37542422
[TBL] [Abstract][Full Text] [Related]
6. Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology.
Seferović PM; Fragasso G; Petrie M; Mullens W; Ferrari R; Thum T; Bauersachs J; Anker SD; Ray R; Çavuşoğlu Y; Polovina M; Metra M; Ambrosio G; Prasad K; Seferović J; Jhund PS; Dattilo G; Čelutkiene J; Piepoli M; Moura B; Chioncel O; Ben Gal T; Heymans S; de Boer RA; Jaarsma T; Hill L; Lopatin Y; Lyon AR; Ponikowski P; Lainščak M; Jankowska E; Mueller C; Cosentino F; Lund L; Filippatos GS; Ruschitzka F; Coats AJS; Rosano GMC
Eur J Heart Fail; 2020 Sep; 22(9):1495-1503. PubMed ID: 32618086
[TBL] [Abstract][Full Text] [Related]
7. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
;
Lancet; 2022 Nov; 400(10365):1788-1801. PubMed ID: 36351458
[TBL] [Abstract][Full Text] [Related]
8. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
Packer M
Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
[TBL] [Abstract][Full Text] [Related]
9. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
Mentz RJ; Brunton SA; Rangaswami J
Cardiovasc Diabetol; 2023 Nov; 22(1):316. PubMed ID: 37974185
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
Anker SD; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Zannad F; Packer M;
Eur J Heart Fail; 2019 Oct; 21(10):1279-1287. PubMed ID: 31523904
[TBL] [Abstract][Full Text] [Related]
11. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
Packer M; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Anker SD; Zannad F;
Eur J Heart Fail; 2019 Oct; 21(10):1270-1278. PubMed ID: 31584231
[TBL] [Abstract][Full Text] [Related]
13. [ANMCO practical guide for sodium-glucose cotransporter 2 inhibitor use in patients with heart failure].
Di Fusco SA; Spinelli A; Aquilani S; Gulizia MM; Gabrielli D; Oliva F; Colivicchi F
G Ital Cardiol (Rome); 2023 Jan; 24(1):66-74. PubMed ID: 36573513
[TBL] [Abstract][Full Text] [Related]
14. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis.
Usman MS; Bhatt DL; Hameed I; Anker SD; Cheng AYY; Hernandez AF; Jones WS; Khan MS; Petrie MC; Udell JA; Friede T; Butler J
Lancet Diabetes Endocrinol; 2024 Jul; 12(7):447-461. PubMed ID: 38768620
[TBL] [Abstract][Full Text] [Related]
15. Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Seidu S; Kunutsor SK; Topsever P; Khunti K
Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00303. PubMed ID: 34636161
[TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.
Natale P; Tunnicliffe DJ; Toyama T; Palmer SC; Saglimbene VM; Ruospo M; Gargano L; Stallone G; Gesualdo L; Strippoli GF
Cochrane Database Syst Rev; 2024 May; 5(5):CD015588. PubMed ID: 38770818
[TBL] [Abstract][Full Text] [Related]
17. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
Rao S
Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
[TBL] [Abstract][Full Text] [Related]
18. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
Aguilar-Gallardo JS; Correa A; Contreras JP
Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):311-321. PubMed ID: 34264341
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials.
Tsai WC; Hsu SP; Chiu YL; Yang JY; Pai MF; Ko MJ; Tu YK; Hung KY; Chien KL; Peng YS; Wu HY
BMJ Open; 2022 Oct; 12(10):e060655. PubMed ID: 36241355
[TBL] [Abstract][Full Text] [Related]
20. Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): protocol for a randomised controlled trial.
Raven LM; Muir CA; Kessler Iglesias C; Bart NK; Muthiah K; Kotlyar E; Macdonald P; Hayward CS; Jabbour A; Greenfield JR
BMJ Open; 2023 Mar; 13(3):e069641. PubMed ID: 36990488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]